{"filing":{"accession_number":"0001601485-26-000048","cik":"0001601485","ticker":"ELTX","company_name":"Elicio Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"angn-20260617.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000048/angn-20260617.htm"},"events":[{"id":11448,"run_id":10051,"accession_number":"0001601485-26-000048","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The disclosure announces preliminary clinical observations supporting evaluation of ELI-002 7P in combination with checkpoint inhibition and plans for a Phase 1 study in metastatic KRAS pancreatic cancer. This is a material clinical development milestone for a biopharmaceutical company, but does not fit neatly into more specific event categories (not an earnings release, not a formal restatement, not an impairment). The clinical progress and future study plans would affect investor assessment of the company's pipeline and prospects.","company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","filing_date":"2026-06-17","form":"8-K","submitted_at":null,"items":[{"id":8039,"accession_number":"0001601485-26-000048","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces preliminary clinical observations supporting evaluation of ELI-002 7P in combination with checkpoint inhibition and plans for a Phase 1 study in metastatic KRAS pancreatic cancer. This is a material clinical development milestone for a biopharmaceutical company, but does not fit neatly into more specific event categories (not an earnings release, not a formal restatement, not an impairment). The clinical progress and future study plans would affect investor assessment of the company's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T12:04:06.015644+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8039,"accession_number":"0001601485-26-000048","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces preliminary clinical observations supporting evaluation of ELI-002 7P in combination with checkpoint inhibition and plans for a Phase 1 study in metastatic KRAS pancreatic cancer. This is a material clinical development milestone for a biopharmaceutical company, but does not fit neatly into more specific event categories (not an earnings release, not a formal restatement, not an impairment). The clinical progress and future study plans would affect investor assessment of the company's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T12:04:06.015644+00:00","company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","filing_date":"2026-06-17"}]}